Idexx Laboratories Inc. IDXX
What this company does
Written from the business description in IDEXX LABORATORIES INC /DE's annual report to the U.S. Securities and Exchange Commission, filed 20 February 2026. Every sentence was checked against that document before publication.
Revenue compounded at +9.7% a year over five years — but profit grew faster: net income at +12.7%, earnings per share at +14.3%.
The share count fell from 0.09B to 0.08B — the buyback concentrates the same profit into fewer slices.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 66 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 4.3 | 3.9 | 3.7 | 3.4 | 3.2 | 2.7 | 2.4 | 2.2 | 2.0 | 1.8 | 1.6 | 1.5 | 1.4 | 1.3 | 1.2 | 1.1 | 1.0 | 1.0 |
| Operating income $B | 1.4 | 1.1 | 1.1 | 0.9 | 0.9 | 0.7 | 0.6 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
| EBITDA $B | 1.5 | 1.3 | 1.2 | 1.0 | 1.0 | 0.8 | 0.6 | 0.6 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 |
| Income tax $B | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Net income $B | 1.1 | 0.9 | 0.8 | 0.7 | 0.7 | 0.6 | 0.4 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 |
| Free cash flow $B | 1.1 | 0.8 | 0.8 | 0.4 | 0.6 | 0.5 | 0.3 | 0.3 | 0.3 | 0.3 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 |
| EPS, diluted $ | 13.08 | 10.67 | 10.06 | 8.03 | 8.60 | 6.71 | 4.89 | 4.26 | 2.94 | 2.44 | 2.05 | 1.79 | 1.74 | 3.17 | 2.78 | 2.37 | 2.01 | 1.87 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | 66.2 | 57.7 | 80.7 | 104.6 | 112.7 | 143.7 | 509.3 | · | · | · | 1150.5 | 57.2 | 32.5 | 30.3 | 29.1 | 26.0 | 23.8 | · |
| Shares out B | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | · | · | · | · | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
This company against its peers
Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.